Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:

  • Evercore ISI 3rd Annual HealthCONx Conference
    Date: December 1, 2020
    Live Presentation Time: 10:55 am ET
  • Piper Sandler 32nd Annual Virtual Healthcare Conference
    Date: December 2, 2020
    Pre-recorded presentation available online

Executive management will also participate in one-on-one meetings during the duration of the conferences.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at Recordings will be available for 30 days following each event.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at or follow the Company on social media: LinkedIn at and Twitter @PhathomPharma.


Media Contact:
Nick Benedetto

Investor Contact:
Todd Branning

Primary Logo

Back to news